Discontinuation of β-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial
Authors:
- Ki Hong ChoiKCKi Hong Choi
- Juwon KimJKJuwon Kim
- Danbee KangDKDanbee Kang
- Joon-Hyung DohJDJoon-Hyung Doh
- Juhan KimJKJuhan Kim
- Yong Hwan ParkYPYong Hwan Park
- Sung Gyun AhnSASung Gyun Ahn
- Weon KimWKWeon Kim
- Jong Pil ParkJPJong Pil Park
- Sang Min KimSKSang Min Kim
- Byung-Ryul ChoBCByung-Ryul Cho
- Chang-Wook NamCNChang-Wook Nam
Open Access
Abstract
Introduction There is a lack of evidence to support the effectiveness of prolonged β-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction. Methods and analysis The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing β-blocker therapy after ≥1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejection fraction >40%) who have been continuing β-blocker therapy for ≥1 year after AMI. A total of 2540 patients will be randomised 1:1 to continuation of β-blocker therapy or not. Randomisation will be stratified according to the type of AMI (ie, ST-segment-elevation MI or non-ST-segment-elevation MI), type of β-blocker (carvedilol, bisoprolol, nebivolol or other) and participating centre. The primary study endpoint is a composite of all-cause death, MI and hospitalisation for HF over a median follow-up period of 3.5 years (minimum, 2.5 years; maximum, 4.5 years). Adverse effects related to β-blocker therapy, the occurrence of atrial fibrillation, medical costs and Patient-reported Outcomes Measurement Information system-29 questionnaire responses will also be collected as secondary endpoints. Ethics and dissemination Ethics approval for this study was granted by the Institutional Review Board of Samsung Medical Center (no. 2020-10-176). Informed consent is obtained from every participant before randomisation. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences. Trial registration number ClinicalTrials.gov, NCT04769362.Keywords
Funding Information
- Patient-Centered Clinical Research Coordinating Center funded by the Ministry of Health & Welfare, Republic of Korea (HC20C0161)
This publication has 32 references indexed in Scilit:
- βeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trialAmerican Heart Journal, 2023
- Implementation of High-Sensitivity Cardiac Troponin Assays in the United StatesJACC, 2022
- Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research ConsortiumJACC: Heart Failure, 2020
- BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point studyAmerican Heart Journal, 2019
- β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular DysfunctionJACC, 2017
- 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary SyndromesJACC, 2014
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task ForceValue in Health, 2013
- Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary SyndromesThe MIRACL Study: A Randomized Controlled TrialJAMA, 2001
- Sympathetic Activation in Heart Failure and Its Treatment With β-BlockadeArchives of internal medicine (1960), 1999
- A Randomized Trial of Propranolol in Patients With Acute Myocardial InfarctionJAMA, 1982